Adjuvant cisplatin for NSCLC raises non-cancer mortality risk By Afsaneh Gray.
Adjuvant cisplatin for NSCLC raises non-cancer mortality risk By Afsaneh Gray, medwireNews Reporter Re-analysis of data from the International Adjuvant Lung Tumor Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancers mortality in patients with non-small-cell lung cancer . Nevertheless, the chemotherapy also reduced the chance of local cancers relapse and of non-brain metastases, with the researchers estimating that over fifty % of patients may take advantage of the treatment, whereas the harmful effects on non-cancer mortality only became significant after 5 years.5 years edmdrx.com .
Brewer concludes in that publication, ‘it appears clear that huge segments of the population are in risk for toxicities from free copper and free iron and. It appears clear that preventive measures should begin now.’ The fifth publication entitled, ‘The Risks of Copper Toxicity Contributing to Cognitive Decline in the Maturing Population also to Alzheimer’s Disease,’ was released in the June 2009 issue of the Journal of the American College of Nutrition. Based on the ‘Copper Hypothesis’ outlined in the paper by Dr. Brewer, ‘the epidemics of MCI and AD inside our population over age 50 is partly due to the ingestion of inorganic copper in normal water and copper health supplements.’ George J.